$ACOR (Acorda Therapeutics, Inc.)

$ACOR {{ '2016-01-11T22:22:42+0000' | timeago}} • Announcement

$ACOR reported AMPYRA (dalfampridine) extended release tablets, 10 mg unaudited net sales for 4Q15 of $121MM. Unaudited full-year 2015 net sales were $436MM, up approx. 19% YoverY. $ACOR's 2016 guidance for AMPYRA is of net revenue of $475-485MM, R&D expense of $165-175MM, and SG&A expense of $195-205MM, excluding share-based compensation.

$ACOR {{ '2017-08-29T11:50:07+0000' | timeago}} • Announcement

$ACOR received a Refusal to File (RTF) letter from the FDA regarding its New Drug Application (NDA) for Inbrija (CVT-301, levodopa inhalation powder). Inbrija is an investigational treatment for symptoms of OFF periods in people with Parkinson's disease taking a carbidopa/levodopa regimen.

$ACOR {{ '2017-06-29T20:59:19+0000' | timeago}} • Announcement

$ACOR submits New Drug Application (NDA) to FDA for Inbrija, a potential therapy for patients with Parkinson’s disease. Acorda Therapeutics plans to file a Marketing Authorization Application (MAA) in Europe for Inbrija by the end of 2017.

$ACOR {{ '2017-06-06T13:47:37+0000' | timeago}} • Announcement

$ACOR presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically significant, clinically meaningful improvement in motor function, as measured by the Unified Parkinson's Disease Rating Scale - Part III (UPDRS III) in people with Parkinson's experiencing OFF periods.

$ACOR {{ '2017-04-05T15:13:28+0000' | timeago}} • Announcement

$ACOR expects to incur about $8MM of pretax charges for severance and other costs related to its corporate restructuring, primarily during 2Q17. $ACOR expects to be cash flow positive for 2017. The company plans to file a New Drug Application (NDA) for CVT-301 with the FDA in 2Q17.

$ACOR {{ '2017-04-05T15:13:11+0000' | timeago}} • Announcement

$ACOR announced a corporate restructuring to reduce its cost structure, focus resources on its two late-stage programs, CVT-301 and tozadenant, and maximize patient access to AMPYRA at least through July 2018.  $ACOR will reduce headcount by about 20% and expects to realize annualized cost savings of about $21MM beginning in 2Q17.

$ACOR {{ '2017-03-31T17:14:35+0000' | timeago}} • Announcement

$ACOR said the United States District Court for the District of Delaware issued decision to invalidate four patents related to Ampyra (dalfampridine) Extended Release Tablets. The company will appeal the ruling on these patents.

$ACOR {{ '2017-02-22T14:10:35+0000' | timeago}} • Announcement

$ACOR appointed  Catherine D. Strader, to its BoD, effective Feb. 17, 2017. Currently, Strader is the founding partner at Synergy Partners R&D Solutions. He will be up for re-election in 2018.

$ACOR {{ '2017-02-14T20:19:54+0000' | timeago}} • Webcast

$ACOR said that on the pipeline front, CVT-301 and Tozadenant are the top priorities. The company added that it is expecting key pivotal data by 1Q17 for Tozadenant. Therefore, these two are the main priorities by far for $ACOR.

$ACOR {{ '2017-02-14T19:49:06+0000' | timeago}} • Webcast

$ACOR expects its SG&A expense for 2017 to be in the range of $195-205MM, flat from 2016. R&D expense for the quarter was $53.8MM, including $3MM in share based compensation, up from $44MM in 4Q15. The increase in R&D expense was mainly due to R&D expenses for Biotie and increased investments in the late stage development programs.

$ACOR {{ '2017-02-14T11:30:48+0000' | timeago}} • Announcement

$ACOR said the positive phase 3 data from its pivotal trial of Parkinson's disease therapy CVT-301 represents a major milestone for the company. $ACOR plans to file a New Drug Application in 2Q17, pending the results of two long-term safety studies. Data from these studies are expected in 1Q17.

$ACOR {{ '2017-02-14T11:28:16+0000' | timeago}} • Announcement

$ACOR expects 2017 Ampyra revenue of $535-545MM. The company predicts 2017 research and development expenses of $185-195MM and selling, general and administrative expenses of $195-205MM.

$ACOR {{ '2017-02-14T11:26:33+0000' | timeago}} • Announcement

$ACOR's revenue from Ampyra, which will improve walking in patients with multiple sclerosis (MS), for 4Q16 rose 8.4% from last year. About 120,000 people with MS in the U.S. have tried Ampyra since its launch in 2010.

$ACOR {{ '2017-02-14T11:22:44+0000' | timeago}} • Announcement

$ACOR slipped to a 4Q16 loss from a profit last year, due to higher operating expenses, and a provision for income taxes. Net loss was $3.09MM or $0.07 per share compared to a profit of $9.21MM or $0.21 per share last year. Revenue grew to $140.63MM from $130.9MM. Non-GAAP EPS fell to $0.05 from $0.31.

$ACOR {{ '2017-01-09T13:02:45+0000' | timeago}} • Announcement

$ACOR reported Ampyra (dalfampridine) net sales for 4Q16 of $132MM. Full-year net sales for 2016 were $493MM, a rise of about 13% from 2015. For 2017, $ACOR expects Ampyra net sales of $535-545MM, research and development expense of $195-205MM. At year-end 2016, $ACOR sees cash, cash equivalents and investments of about $155MM.

$ACOR {{ '2016-11-21T15:51:27+0000' | timeago}} • Announcement

$ACOR said it will discontinue development of dalfampridine for treatment of post-stroke walking difficulties as the Milestone clinical study did not show sufficient efficacy. As part of the program, a multi-dose pharmacokinetic study confirmed the company has developed a potentially viable once-daily formulation of dalfampridine.

$ACOR {{ '2016-10-13T11:54:34+0000' | timeago}} • Announcement

$ACOR has published results from Phase 1, Phase 2a and preclinical studies of CVT-301, an inhaled form of levodopa, for the treatment of OFF periods in people with Parkinson's disease (PD). PD is a neurodegenerative disorder which results in impaired movement, muscle stiffness and tremors. OFF periods increase as PD progresses.

$ACOR {{ '2016-10-04T12:16:17+0000' | timeago}} • Announcement

Biotechnology company $ACOR said its CFO Michael Rogers has left the company. $ACOR added that David Lawrence, Chief of Business Operations, has assumed the role of Chief, Business Operations & Principal Accounting Officer, while Andrew Hindman, Chief Business Development Officer, has assumed responsibility for Financial Planning & Analysis and IR.

$ACOR {{ '2016-09-30T17:56:23+0000' | timeago}} • Announcement

$ACOR, which acquired Biotie Therapies Corp. in January 2016, gained title to all the shares in Biotie Therapies. Nasdaq Helsinki delisted Biotie shares as title to all shares in Biotie was transferred to $ACOR.

$ACOR {{ '2016-07-01T11:10:19+0000' | timeago}} • Announcement

$ACOR said that Burkhard Blank has assumed the role of Chief Medical Officer effective immediately. Dr. Blank was appointed as the company's interim CMO in Jan. 2016, and previously served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim.

$ACOR {{ '2016-05-20T12:06:15+0000' | timeago}} • Announcement

Biotechnology company $ACOR said it discontinues the development of an investigation therapy PLUMIAZ Nasal Spray, which is currently being studied to treat epilepsy seizure clusters.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
IPXL (Impax Laboratories Inc.)
Wednesday, August 9 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, August 8 2017 - 9:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 3:30pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
DEPO (DepoMed Inc.)
Monday, August 7 2017 - 8:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, August 3 2017 - 11:30am
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Thursday, July 27 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm

AlphaGraphics you may like